Institute of Infectious Diseases, Catholic University, Rome, Italy.
AIDS. 2010 Sep 24;24(15):2408-12. doi: 10.1097/QAD.0b013e32833db989.
In order to analyze the clinical relevance of the pharmacokinetic interactions between vinblastine and antiretrovirals described in literature, we evaluated all HIV-infected patients with Hodgkin's lymphoma treated with vinblastine-containing regimens and combination antiretroviral therapy, in a single clinical center. The use of protease inhibitors was independently associated with WHO grade III-IV neutropenia. Moreover, an inverse correlation between dosage of ritonavir and mean nadir neutrophil count was found. The concomitant administration of vinblastine-containing chemotherapy regimens with protease inhibitors can lead to higher levels of neutropenia than those of different classes of drugs such as nonnucleoside reverse transcriptase inhibitors or integrase inhibitors.
为了分析文献中描述的长春碱与抗逆转录病毒药物之间药代动力学相互作用的临床相关性，我们在一个单一的临床中心评估了所有接受长春碱联合方案和联合抗逆转录病毒治疗的 HIV 感染霍奇金淋巴瘤患者。蛋白酶抑制剂的使用与世界卫生组织（WHO）III-IV 级中性粒细胞减少症独立相关。此外，还发现利托那韦剂量与中性粒细胞最低值之间存在负相关。长春碱联合化疗方案与蛋白酶抑制剂联合应用可导致中性粒细胞减少症的发生率高于非核苷类逆转录酶抑制剂或整合酶抑制剂等不同类别的药物。
